Can Genzyme wait out Sanofi's buyout bid?

Without its now-expired poison pill, Genzyme doesn't have much built-in defense against Sanofi-Aventis, Bloomberg points out today. About the only thing it can do is wait, hoping that investors will continue thinking that Sanofi's price is too low. But dragging its feet may be plenty effective. Report